Alpha 2.0
Login Register
» Articles » PMID: 6845257

Intrapleural Corynebacterium Parvum for Malignant Pleural Effusions

Overview
Journal Thorax
Date 1983 Jan 1
PMID 6845257
Citations 6
Authors
R Felletti
C RAVAZZONI
Affiliations
Soon will be listed here.
Abstract

A pilot study of topical (intrapleural) treatment with Corynebacterium parvum was carried out in 10 patients with malignant pleural effusions complicating primary or secondary neoplasms and necessitating frequent thoracocentesis for symptomatic relief. The method was aspiration of all intrapleural fluid except a small portion left for dilution, and then injection of 7 mg of a preparation of Corynebacterium parvum suspended in 20 ml of normal saline solution. The treatment was repeated in each case as clinical conditions called for further thoracocentesis. In eight of these 10 patients the treatment resulted in prompt reduction of the rate of accumulation of pleural fluid and a striking change of cell sediment composition, with appreciable reduction in or complete disappearance of malignant cells and a rise in lymphocyte and neutrophil polymorph counts. The best responders were patients with primary pleural mesothelioma. Clinical improvement was evident in all responders.

Citing Articles

A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology.

Bibby A, Zahan-Evans N, Keenan E, Comins C, Harvey J, Day H Pilot Feasibility Stud. 2022; 8(1):196.

PMID: 36057634 PMC: 9440504. DOI: 10.1186/s40814-022-01156-3.

Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration.

Mierzejewski M, Korczynski P, Krenke R, Janssen J Respir Res. 2019; 20(1):247.

PMID: 31699094 PMC: 6836467. DOI: 10.1186/s12931-019-1204-x.

Management of recurrent malignant pleural effusion with chemical pleurodesis.

Kilic D, Akay H, Kavukcu S, Kutlay H, Kayi Cangir A, Enon S Surg Today. 2005; 35(8):634-8.

PMID: 16034542 DOI: 10.1007/s00595-005-2996-5.

Corynebacterium parvum for malignant pleural effusions.

Foresti V Thorax. 1995; 50(1):104.

PMID: 7886641 PMC: 473751. DOI: 10.1136/thx.50.1.104.

Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

De Jong W, Steerenberg P, Kreeftenberg J, Tiesjema R, Kruizinga W, VAN NOORLE JANSEN L Cancer Immunol Immunother. 1984; 17(1):18-27.

PMID: 6563941 PMC: 11039122. DOI: 10.1007/BF00205492.

References
1.
Stiksa G, Korsgaard R, SIMONSSON B . Treatment of recurrent pleural effusion by pleurodesis with quinacrine. Comparison between instillation by repeated thoracenteses and by tube drainage. Scand J Respir Dis. 1979; 60(4):197-205. View
2.
Serrou B, Cupissol D . [Pleural effusion. Local treatment by Corynebacterium parvum]. Nouv Presse Med. 1980; 9(25):1777-8. View
3.
Thatcher N, Lamb B, Swindell R, Crowther D . Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days. Cancer. 1981; 47(2):285-90. DOI: 10.1002/1097-0142(19810115)47:2<285::aid-cncr2820470213>3.0.co;2-x. View
4.
MILLAR J, Hunter A, HORNE N . Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax. 1980; 35(11):856-8. PMC: 471397. DOI: 10.1136/thx.35.11.856. View
5.
Mantovani A, Sessa C, Peri G, Allavena P, Introna M, Polentarutti N . Intraperitoneal administration of Corynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: effects on cytotoxicity of tumor-associated macrophages and NK cells. Int J Cancer. 1981; 27(4):437-46. DOI: 10.1002/ijc.2910270404. View